查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2010922

气喘治疗市场：2026-2032年全球市场预测（依产品类型、药物类别、给药途径、通路和最终用户划分）

Asthma Drugs Market by Product Type, Drug Class, Delivery Mode, Distribution Channel, End Users - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，气喘治疗市场价值将达到 257.5 亿美元，到 2026 年将成长至 273.1 亿美元，到 2032 年将达到 396.2 亿美元，复合年增长率为 6.34%。

主要市场统计数据
基准年 2025 257.5亿美元
预计年份：2026年 273.1亿美元
预测年份 2032 396.2亿美元
复合年增长率 (%) 6.34%

对当前气喘治疗格局、医疗设备创新、监管压力和相关人员期望等影响气喘治疗策略的因素进行权威分析。

气喘仍然是一种慢性呼吸系统疾病，持续存在的临床和营运挑战不断推动製药和医疗设备产业的创新。儘管传统的治疗模式侧重于缓解症状和预防病情加重，但精准医疗、医疗设备工程的进步以及向整合式医疗模式的稳步转变正在重塑临床路径和采购重点。在此背景下，从製造商到医疗服务提供者和保险公司等相关人员都在重新思考产品系列、患者支援服务和分销策略，以满足不断变化的患者期​​望、监管要求和技术发展趋势。

医疗设备与数位技术的融合、个人化治疗路径、不断变化的报销重点以及供应链的韧性，正在重塑气喘治疗领域的竞争优势。

气喘治疗领域正经历着一场变革性的转变，多种因素交织在一起，重新定义了竞争优势和病患疗效。首先，医疗设备的创新正在超越简单的药物输送机制，将吸入器和雾化器转变为整合了感测器、行动应用程式和云端分析的数位化生态系统。这一趋势正在改变价值提案，使其不再仅仅关注产品本身，而是透过增强药物依从性追踪和支持主导在每次就诊时进行干预，从而提升疗效和患者参与度。

对美国在 2025 年实施的关税措施如何影响气喘治疗产业的采购成本、製造地和筹资策略进行分析性回顾。

美国将于2025年对某些商品加征关税的政策决定，对气喘药物的供应链、商业策略和长期投资决策产生了多方面的影响。对某些原料、成品医疗设备和零件征收的进口关税，增加了部分依赖全球采购的製造商的收货成本。因此，采购团队和契约製造加快了重新评估供应商合约、寻找近岸和国内替代方案以及谈判长期供应协议的步伐，以减轻成本波动的影响。

透过综合細項分析，揭示产品类型、药物分类、给药途径、分销管道和最终用户特征如何影响临床引入和商业策略。

从产品类型、药物类别、给药途径、分销管道和终端用户观点进行細項分析，可以清楚揭示商业性和临床动态。依产品类型划分，吸入器、雾化器和片剂/胶囊剂型各有不同的市场导向因素。吸入器和雾化器优先考虑设备的人体工学设计、给药准确性和提高遵守用药，而口服製剂则强调特定患者群体的全身耐受性和用药便利性。因此，产品开发团队必须将研发投入与设备易用性和病患偏好资料结合，以最大限度地提高临床渗透率。

从区域观点看美洲、欧洲、中东和非洲以及亚太地区的监管复杂性、支付方期望和商业性实践。

区域趋势正在影响美洲、欧洲、中东和非洲以及亚太地区的监管路径、报销框架和商业重点，为气喘药物领域的相关人员带来不同的机会和挑战。在美洲，复杂的支付方审查和采购流程促使人们更加重视真实世界疗效、成本效益证据以及能够显着减少气喘急性发作和住院治疗的服务模式。在该地区运营的製造商正优先考虑全面的卫生经济学数据和整合的患者支持，以满足处方集决策者和大规模综合医疗保健网络的需求。

老牌製药公司、医疗设备创新者和数位领域的新参与企业如何透过产品和服务捆绑、策略联盟和基于证据的差异化来竞争？

气喘治疗市场的竞争格局由老牌製药巨头、专业医疗设备创新者、契约製造组织 (CMO) 和新兴数位医疗公司组成。关键的商业策略强调透过产品和服务组合实现差异化，将可靠的药理作用与便捷的使用方法、用药依从性支持以及真实世界数据 (REW) 生成相结合。投资长期病人参与解决方案和医疗设备专业人员教育的公司正在为患者转向其他疗法设置明确的障碍，尤其是在维持治疗领域，因为用药依从性和给药技术对临床结果有显着影响。

为商业、製造和临床领导者提供切实可行的策略步骤，以增强韧性、改善患者预后并推动符合支付方需求的价值提案。

产业领导者应优先采取一系列切实可行的措施，以兼顾临床价值、业务永续营运和商业性灵活性。首先，他们应考虑供应商多元化，并将关键医疗设备组件的生产转移到近岸地区，以降低关税相关成本飙升和全球物流中断带来的风险。此外，还应制定情境规划并采用灵活的合约模式，以便在需要时快速更换供应商。

采用严谨的混合方法研究途径，结合相关人员访谈、监管审查、证据整合和情境分析，以确保获得可靠且可操作的见解。

本报告的研究结合了多种定性和定量方法，以确保获得全面而深入的见解。主要研究包括对各类利害关係人进行结构化访谈，包括呼吸科医生、呼吸治疗师、医院采购负责人、药房主任、支付方以及医疗设备製造商和公司的高级商务相关人员。除访谈外，还与临床医生和支付方举行了咨询圆桌会议，以检验他们对治疗模式和报销优先事项的解释。

一项权威的综合分析强调了医疗设备创新、真实世界数据和有韧性的供应链对于气喘治疗的持续成功至关重要的原因。

总之，气喘治疗正处于一个转折点，医疗设备的进步、实证医学证据的累积、监管方面的细微差别以及供应链策略，都对商业性可行性和病患益处产生影响。那些透过采用连网型设备技术、投资上市后证据以及强化供应链来整合这些因素的机构，将更有能力满足临床医生和支付方的期望，同时提高患者的依从性和治疗效果。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：气喘治疗市场：依产品类型划分

  • 吸入器
  • 喷雾器
  • 片剂和药片

第九章：气喘治疗市场：依药物类别划分

  • 沙丁胺醇
  • β-激动剂
  • 支气管扩张剂
  • 皮质类固醇
  • 白三烯调节剂

第十章：气喘治疗市场：依给药方式划分

  • 吸入剂
  • 口服

第十一章：气喘治疗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章：气喘治疗市场：依最终用户划分

  • 门诊手术中心
  • 居家照护设施
  • 医院和诊所

第十三章：气喘治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章气喘治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：气喘治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国气喘治疗市场

第十七章：中国气喘治疗药物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • ALK-Abello A/S
  • Amphastar Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • CHIESI Farmaceutici SpA
  • Cipla Limited
  • Dr.Reddy's Laboratories Ltd
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Hetero Labs Limited
  • Lallemand Inc.
  • Merck KGaA
  • Mundipharma International Limited
  • NIOX Group PLC
  • Novartis AG
  • Novo Holdings
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Sanner GmbH
  • Sanofi SA
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Verona Pharma PLC
  • Viatris, Inc.
Product Code: MRR-434CCDA05226

The Asthma Drugs Market was valued at USD 25.75 billion in 2025 and is projected to grow to USD 27.31 billion in 2026, with a CAGR of 6.34%, reaching USD 39.62 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 25.75 billion
Estimated Year [2026] USD 27.31 billion
Forecast Year [2032] USD 39.62 billion
CAGR (%) 6.34%

An authoritative orientation to the current therapeutic environment, device innovation, regulatory pressures, and stakeholder expectations that define asthma drug strategies

Asthma remains a chronic respiratory condition with persistent clinical and operational challenges that continue to drive innovation across pharmaceutical and device sectors. Treatment paradigms have historically centered on symptom relief and exacerbation prevention, but a steady shift toward precision therapeutics, improved device engineering, and integrated care models is reshaping clinical pathways and procurement priorities. Against this backdrop, stakeholders from manufacturers to providers and payers are reassessing product portfolios, patient support services, and distribution strategies to respond to changing patient expectations, regulatory requirements, and technological possibilities.

The contemporary landscape reflects an intersection of clinical science and systems thinking. Advances in inhaler design and connectivity are enabling adherence monitoring and remote management, while evolving clinical guidance encourages earlier intervention and stratified therapy selection. Concurrently, supply chain considerations, manufacturing specialization, and cost containment pressures are prompting reassessments of sourcing and production footprints. Taken together, these dynamics have created both disruption and opportunity for organizations that can combine clinical credibility with operational agility and data-driven decision making.

How device-digital convergence, personalized treatment pathways, evolving reimbursement priorities, and supply chain resilience are reshaping competitive advantage in asthma therapeutics

The asthma therapeutics environment is experiencing transformative inflection driven by several converging forces that are redefining competitive advantage and patient outcomes. First, device innovation has moved beyond simple delivery mechanics toward integrated digital ecosystems that pair inhalers and nebulizers with sensors, mobile applications, and cloud analytics. This trend enhances medication adherence tracking and enables provider-led interventions between visits, thereby shifting value propositions toward outcomes and engagement rather than product-only offerings.

Second, clinical personalization is gaining momentum as clinicians and payers prioritize phenotype- and biomarker-driven approaches for moderate to severe disease management. Consequently, treatment pathways are becoming more nuanced, favoring targeted agents and combination strategies for patients with distinct inflammatory profiles. Third, regulatory and reimbursement landscapes are evolving to reward real-world effectiveness and cost containment, which increases the importance of robust post-market evidence generation and payer engagement. Moreover, supply chain resilience and procurement agility have grown in importance following global disruptions, prompting manufacturers to reassess sourcing, inventory strategies, and local manufacturing options.

Finally, patient expectations and care delivery models are shifting in parallel. Telehealth adoption, decentralized care, and home-based monitoring have expanded the touchpoints for asthma management and require integrated solutions that simplify use and improve adherence. In sum, these transformative shifts favor organizations that can integrate device innovation, clinical evidence, supply chain adaptability, and stakeholder-aligned value propositions into coherent commercial strategies.

An analytical review of how the United States tariff measures enacted in 2025 have influenced sourcing costs, manufacturing footprints, and procurement strategies across asthma therapeutics

The policy decision to implement new tariffs in the United States in 2025 has had multifaceted implications for the asthma therapeutics supply chain, commercial strategies, and long-term investment choices. Import duties on select raw materials, finished devices, and components increased landed costs for certain manufacturers that rely on globalized sourcing. As a result, procurement teams and contract manufacturers accelerated efforts to re-evaluate supplier contracts, identify nearshore and domestic alternatives, and negotiate longer-term supply agreements to mitigate cost volatility.

Consequently, manufacturers with vertically integrated manufacturing or diversified supplier bases found greater stability, while those with concentrated exposure to affected import categories faced operational pressure. In response, several organizations prioritized reprioritization of capital spend toward local production lines for devices and assembly operations, even as they continued to balance unit economics against regulatory and quality compliance costs. Moreover, tariff-driven cost pressures have influenced pricing discussions with distributors and payers, encouraging stakeholders to emphasize value-added services such as adherence programs and patient support to sustain commercial positioning.

From a strategic standpoint, the tariff environment amplified the importance of agility in sourcing and product design. Firms that proactively redesigned components to use alternative materials or modular architectures saw improved resilience. Additionally, transitional measures-such as re-classifying components, leveraging free trade agreements where applicable, and increasing inventory buffers-helped some organizations absorb short-term shocks. Looking forward, the cumulative impact of these policy changes is prompting long-term reconsideration of supply chain footprint strategies, manufacturing investments, and the balance between cost optimization and continuity of care for patients reliant on inhalers, nebulizers, and oral therapies.

Integrated segmentation analysis revealing how product types, drug classes, delivery modes, distribution channels, and end-user contexts shape clinical adoption and commercial strategies

Segmentation insights reveal distinct commercial and clinical dynamics when examined through product type, drug class, delivery mode, distribution channel, and end-user lenses. When framed by product type, inhalers, nebulizers, and tablets and pills demonstrate divergent adoption drivers: inhalers and nebulizers prioritize device ergonomics, dosing accuracy, and adherence facilitation, while oral formulations emphasize systemic tolerability and convenience for particular patient cohorts. As a result, product development teams must align R&D investments with device usability and patient preference data to maximize clinical uptake.

Viewing the landscape by drug class highlights unique therapeutic and regulatory considerations. Albuterol and beta agonists primarily address acute symptom relief and immediate bronchodilation needs, whereas bronchodilators and corticosteroids form the backbone of maintenance regimens that require longitudinal adherence and safety monitoring. Leukotriene modifiers offer alternative or adjunctive pathways for specific inflammatory phenotypes and can be positioned as oral options for patients who prefer or require noninhaled therapy. Therefore, formulary positioning and clinical messaging must differentiate acute rescue therapies from maintenance approaches while accounting for safety profiles and route-specific advantages.

Delivery mode-classified broadly as inhalable or oral-shapes both clinical outcomes and patient acceptance. Inhalable therapies offer targeted pulmonary deposition and rapid onset, but they demand patient technique competency and sometimes a higher degree of training and follow-up. Oral therapies provide convenience and familiar dosing formats but may present different systemic exposure profiles and adherence challenges. Consequently, commercialization strategies should integrate patient education initiatives and device training programs for inhalable products while reinforcing adherence supports for oral regimens.

Distribution channel considerations further inform go-to-market approaches, with hospital pharmacies, online pharmacies, and retail pharmacies each serving distinct buyer behaviors and logistical constraints. Hospital pharmacies often handle acute and high-acuity cases with institutional purchasing frameworks, online pharmacies provide convenience and subscription models that support chronic therapy continuity, and retail pharmacies remain critical for point-of-care counseling and immediate access. Aligning distribution strategies with anticipated prescribing patterns and payer pathways is therefore essential for maintaining product availability and patient adherence.

Finally, end-user segmentation across ambulatory surgery centers, home care settings, and hospitals and clinics underscores varied utilization contexts and support requirements. Ambulatory surgery centers may prioritize short-acting agents for peri-procedural management, home care settings demand durable and easy-to-use devices with remote monitoring capabilities, and hospitals and clinics require high-reliability supply and comprehensive clinical support materials. Integrating these segmentation layers supports a nuanced commercial playbook that balances product design, evidence generation, and service delivery to meet the expectations of clinicians, caregivers, and patients.

A regionally differentiated perspective on regulatory complexity, payer expectations, and commercial execution across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics influence regulatory pathways, reimbursement frameworks, and commercial priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific, creating distinct opportunities and constraints for asthma therapeutics stakeholders. In the Americas, payer scrutiny and procurement sophistication drive an emphasis on real-world outcomes, cost-effectiveness evidence, and service models that demonstrably reduce exacerbations and hospital admissions. Manufacturers operating in this region are prioritizing comprehensive health economic dossiers and integrated patient support to satisfy formulary decision-makers and large integrated delivery networks.

Across Europe, Middle East & Africa, heterogeneous regulatory regimes and reimbursement environments necessitate adaptive market entry strategies. In some European countries, centralized procurement and value-based contracting play increasing roles, while in parts of the Middle East and Africa, access challenges and infrastructure variability favor robust distribution partnerships and capacity-building programs. Consequently, cross-border strategies must balance centralized evidence generation with locally tailored payer engagement and supply chain solutions.

The Asia-Pacific region presents both rapid adoption potential and complexity due to diverse healthcare systems, regulatory standards, and patient demographics. Many jurisdictions in this region are fast adopters of digital health technologies, providing fertile ground for connected inhaler solutions and remote monitoring integration. At the same time, manufacturers must navigate price sensitivity and local manufacturing expectations, which often require creative commercialization models, technology transfers, and strategic partnerships to support sustainable access and scale. Across all regions, coordinated evidence generation, regulatory foresight, and distribution planning remain central to successful market penetration and long-term product sustainability.

How incumbent pharmaceutical firms, device innovators, and digital entrants are competing through product-service bundles, strategic alliances, and evidence-driven differentiation

Competitive dynamics in the asthma therapeutics arena reflect a blend of established pharmaceutical incumbents, specialized device innovators, contract manufacturing organizations, and emerging digital health entrants. Leading commercial strategies emphasize differentiation through product-service bundles that combine reliable pharmacology with device usability, adherence supports, and real-world evidence generation. Firms that invest in longitudinal patient engagement solutions and provider education create distinct barriers to substitution, particularly for maintenance therapies where adherence and technique determine clinical outcomes.

Strategic partnerships and alliances have become common mechanisms to accelerate capability building in areas such as connected devices, cloud analytics, and specialty manufacturing. Licensing agreements and co-development arrangements allow established drug developers to integrate hardware and software expertise without sacrificing speed to market. At the same time, contract manufacturers and regional production hubs have increased their strategic importance by offering flexible capacity and regulatory-compliant assembly services that reduce time-to-shelf and improve supply chain robustness.

Product pipeline diversification is also a notable trend, with organizations pursuing incremental device improvements, combination therapies, and enhanced patient support programs as complementary levers to traditional R&D. Meanwhile, competitive differentiation increasingly rests on the ability to demonstrate measurable improvements in adherence, reduction in exacerbations, and cost-effective care pathways through robust post-market studies. Firms that can present coherent clinical and economic narratives to payers and health systems will be best positioned to secure formulary placement and long-term utilization.

Actionable strategic steps for commercial, manufacturing, and clinical leaders to build resilience, enhance patient outcomes, and drive payer-aligned value propositions

Industry leaders should prioritize a set of pragmatic actions that align clinical value with operational resilience and commercial agility. First, diversify supplier bases and consider nearshoring manufacturing for critical device components to reduce exposure to tariff-related cost spikes and global logistics disruptions. This step should be complemented by scenario planning and flexible contracting models that allow rapid supplier substitution when necessary.

Second, invest in connected-device capabilities and patient engagement platforms that demonstrably improve adherence and collect real-world outcomes. Such investments can strengthen payer conversations and create opportunities for outcomes-based contracting. Third, expand evidence-generation programs beyond classical randomized trials to include real-world studies, registries, and health economics analyses that reflect payer and provider decision criteria. These data assets will be critical when negotiating placement with large integrated delivery networks and national health systems.

Fourth, calibrate go-to-market strategies to reflect distribution channel realities and end-user needs; tailor support materials and training programs for hospital pharmacists, retail teams, and home-care providers accordingly. Fifth, pursue selective strategic partnerships to accelerate digital and manufacturing capabilities rather than attempting to build all competencies internally. Finally, engage regulators and payers early to align clinical development plans with reimbursement requirements, reducing the risk of protracted uptake barriers following product launch. Together, these actions offer a pragmatic roadmap for converting insights into durable competitive advantage.

A rigorous mixed-methods research approach combining stakeholder interviews, regulatory review, evidence synthesis, and scenario analysis to ensure credible actionable insights

The research underpinning this report combined multiple qualitative and quantitative approaches to ensure robust, triangulated insights. Primary research included structured interviews with a range of stakeholders: practicing pulmonologists, respiratory therapists, hospital procurement officers, pharmacy directors, payers, and senior commercial leaders from manufacturers and device firms. These interviews were complemented by advisory roundtables with clinicians and payers to validate interpretation of practice patterns and reimbursement priorities.

Secondary research encompassed systematic reviews of public regulatory guidance, clinical practice guidelines, product labeling, and peer-reviewed literature to construct a comprehensive evidence baseline. Trade publications, regulatory filings, and corporate disclosures aided understanding of competitive posture and pipeline dynamics. Data synthesis followed a triangulation framework in which primary insights were cross-referenced with documentary evidence to identify convergent themes and reduce bias.

Analytical methods included qualitative thematic coding for interview transcripts, scenario analysis to test supply chain and tariff impacts under alternative assumptions, and payer pathway mapping to capture regional reimbursement nuances. Where applicable, sensitivity analyses were performed to assess the behavioral implications of device adoption and evidence generation on formulary positioning. Throughout, quality assurance measures ensured consistency and traceability of findings, including independent review of methodology and source logs.

A conclusive synthesis underscoring why device innovation, real-world evidence, and resilient supply chains are essential to sustainable success in asthma therapeutics

In conclusion, the asthma therapeutics landscape is at an inflection point where device evolution, evidence generation, regulatory nuance, and supply chain strategy jointly determine commercial viability and patient impact. Organizations that integrate these dimensions-by deploying connected-device technologies, investing in post-market evidence, and fortifying supply chains-will be better equipped to meet clinician and payer expectations while improving adherence and outcomes for patients.

Moreover, the policy and economic environment, including tariff-driven cost pressures and regional access dynamics, underscores the need for agility and forward-looking operational choices. By aligning product design with distribution realities and clinical practice patterns, companies can create defensible value propositions that resonate with stakeholders across hospitals, home care settings, and pharmacies. The path forward favors firms that are proactive in forming strategic partnerships, responsive to payer evidence requirements, and disciplined in execution, thereby translating insight into sustainable value for patients and health systems alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Asthma Drugs Market, by Product Type

  • 8.1. Inhalers
  • 8.2. Nebulizers
  • 8.3. Tablets & Pills

9. Asthma Drugs Market, by Drug Class

  • 9.1. Albuterol
  • 9.2. Beta Agonists
  • 9.3. Brochodilators
  • 9.4. Corticosteroids
  • 9.5. Leukotriene Modifiers

10. Asthma Drugs Market, by Delivery Mode

  • 10.1. Inhalable
  • 10.2. Oral

11. Asthma Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Asthma Drugs Market, by End Users

  • 12.1. Ambulatory Surgery Centers
  • 12.2. Home Care Settings
  • 12.3. Hospitals & Clinics

13. Asthma Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Asthma Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Asthma Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Asthma Drugs Market

17. China Asthma Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. ALK-Abello A/S
  • 18.6. Amphastar Pharmaceuticals, Inc.
  • 18.7. AstraZeneca PLC
  • 18.8. Bayer AG
  • 18.9. Boehringer Ingelheim International GmbH
  • 18.10. CHIESI Farmaceutici S.p.A.
  • 18.11. Cipla Limited
  • 18.12. Dr.Reddy's Laboratories Ltd
  • 18.13. F. Hoffmann-La Roche Ltd.
  • 18.14. GlaxoSmithKline PLC
  • 18.15. Hetero Labs Limited
  • 18.16. Lallemand Inc.
  • 18.17. Merck KGaA
  • 18.18. Mundipharma International Limited
  • 18.19. NIOX Group PLC
  • 18.20. Novartis AG
  • 18.21. Novo Holdings
  • 18.22. OPKO Health, Inc.
  • 18.23. Pfizer Inc.
  • 18.24. Sanner GmbH
  • 18.25. Sanofi S.A.
  • 18.26. Sunovion Pharmaceuticals Inc.
  • 18.27. Teva Pharmaceutical Industries Ltd.
  • 18.28. Verona Pharma PLC
  • 18.29. Viatris, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ASTHMA DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ASTHMA DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ASTHMA DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ASTHMA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ASTHMA DRUGS MARKET SIZE, BY TABLETS & PILLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ASTHMA DRUGS MARKET SIZE, BY TABLETS & PILLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ASTHMA DRUGS MARKET SIZE, BY TABLETS & PILLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ALBUTEROL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ALBUTEROL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ALBUTEROL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BETA AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BETA AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BETA AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BROCHODILATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BROCHODILATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BROCHODILATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ASTHMA DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ASTHMA DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ASTHMA DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ASTHMA DRUGS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ASTHMA DRUGS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ASTHMA DRUGS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ASTHMA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ASTHMA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ASTHMA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ASTHMA DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ASTHMA DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ASTHMA DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ASTHMA DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS ASTHMA DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ASTHMA DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 111. GCC ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GCC ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. GCC ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 114. GCC ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 115. GCC ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. GCC ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 129. G7 ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. G7 ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. G7 ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 132. G7 ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 133. G7 ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. G7 ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 135. NATO ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NATO ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NATO ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 138. NATO ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 139. NATO ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. NATO ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)